P. Brissot

P. Brissot, D. Guyader, Y. Deugnier, 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Inhibition of hepatitis B virus production associated with high levels of intracellular viral DNA intermediates in iron-depleted HepG2.2.15 cells.

G. Lescoat, P. Brissot, C. Guguen-Guillouzo, 2001, Journal of hepatology.

Respective value of alkaline phosphatase, gamma-glutamyl transpeptidase and 5' nucleotidase serum activity in the diagnosis of cholestasis: a prospective study of 80 patients.

P. Brissot, D. Guyader, Y. Deugnier, 2000, Journal of clinical gastroenterology.

Redox active plasma iron in C282Y/C282Y hemochromatosis.

M. Pouchard, Z. Cabantchik, P. Brissot, 2005, Blood.

Redox active plasma iron in C 282 Y / C 282 Y hemochromatosis

M. Pouchard, P. Brissot, O. Loréal, 2005 .

Serum ceruloplasmin and ferroxidase activity are not decreased in hepatic failure related to alcoholic cirrhosis: clinical and pathophysiological implications.

M. Pouchard, P. Brissot, R. Moirand, 2004, Alcoholism, clinical and experimental research.

Iron Overload: Diagnosis, Complications, and Management

P. Brissot, 2016 .

Preneoplastic significance of hepatic iron–free foci in genetic hemochromatosis: A study of 185 patients

P. Brissot, Y. Deugnier, L. Powell, 1993, Hepatology.

Effect of alcohol consumption on liver stiffness measured by transient elastography.

P. Brissot, R. Moirand, D. Guyader, 2013, World journal of gastroenterology.

Iron disorders of genetic origin: a changing world.

P. Brissot, O. Loréal, E. Bardou-Jacquet, 2011, Trends in molecular medicine.

Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights.

M. Vérin, P. Brissot, Kunihiro Yoshida, 2002, Journal of hepatology.

Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives.

J. L. Le Gall, P. Brissot, R. Moirand, 1999, Gastroenterology.

Hemochromatosis: Clinical spectrum of hepatic disease in hemochromatosis

P. Brissot, 2000 .

A genotypic study of 217 unrelated probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria.

J. L. Le Gall, P. Brissot, R. Moirand, 1999, Journal of hepatology.

Regulation of ferritin and transferrin receptor expression by iron in human hepatocyte cultures.

G. Lescoat, P. Jégo, P. Brissot, 1993, Journal of hepatology.

Effect of ornithine on albumin and transferrin secretions in rat and human hepatocyte cultures

G. Lescoat, P. Brissot, N. Hubert, 1990 .

Kinetic evaluation of free malondialdehyde and enzyme leakage as indices of iron damage in rat hepatocyte cultures. Involvement of free radicals.

G. Lescoat, P. Brissot, J. Cillard, 1990, Biochemical pharmacology.

Effects of iron overload on transferrin secretion by cultured fetal rat hepatocytes

G. Lescoat, A. Guillouzo, P. Brissot, 1989, Biology of the cell.

Effect of ornithine on transferrin secretion of rat and human hepatocyte cultures.

G. Lescoat, P. Brissot, B. Desvergne, 2008, Liver.

Iron-mediated effect of alcohol on hepatocyte differentiation in HepaRG cells.

G. Lescoat, P. Brissot, R. Moirand, 2013, Chemico-biological interactions.

Ethanol effect on cell proliferation in the human hepatoma HepaRG cell line: relationship with iron metabolism.

G. Lescoat, P. Brissot, R. Moirand, 2011, Alcoholism, clinical and experimental research.

Role of non-transferrin-bound iron in the pathogenesis of iron overload and toxicity.

P. Brissot, O. Loréal, 2002, Advances in experimental medicine and biology.

Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method.

P. Brissot, D. Guyader, O. Loréal, 2000, Journal of hepatology.

Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin.

P. Brissot, O. Loréal, R. Hider, 1999, Analytical biochemistry.

Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non‐transferrin‐bound iron in rats

P. Brissot, A. Hofmann, C. Schteingart, 1997, Hepatology.

Regulation of ferritin expression by alcohol in a human hepatoblastoma cell line and in rat hepatocyte cultures

G. Lescoat, P. Brissot, R. Moirand, 1995 .

Magnetic resonance imaging and assessment of liver iron content in genetic hemochromatosis.

C. Jacquelinet, P. Brissot, D. Guyader, 1992, Journal of hepatology.

Iron and platelets: A subtle, under‐recognized relationship

P. Brissot, O. Loréal, M. Troadec, 2021, American journal of hematology.

Hereditary hypotransferrinemia can lead to elevated transferrin saturation and, when associated to HFE or HAMP mutations, to iron overload.

P. Brissot, O. Loréal, Y. Deugnier, 2015, Blood cells, molecules & diseases.

Biochemical aspects of alpha-L-fucosidase in hepatocellular carcinoma.

P. Brissot, Y. Deugnier, J. Bretagne, 1989, Hepatology.

Biochemical aspects of α‐L‐fucosidase in hepatocellular carcinoma

P. Brissot, Y. Deugnier, J. Bretagne, 1989 .

Chelation and mobilization of cellular iron by different classes of chelators.

P. Milgram, J. Libman, A. Shanzer, 1997, Molecular pharmacology.

Evaluation of computed tomography in the assessment of liver iron overload. A study of 46 cases of idiopathic hemochromatosis.

M. Simon, P. Brissot, M. Bourel, 1989, Gastroenterology.

Diagnosis and treatment of HFE-haemochromatosis

G. Lescoat, P. Brissot, O. Loréal, 2009 .

Current approaches to the management of hemochromatosis.

P. Brissot, F. De Bels, 2006, Hematology. American Society of Hematology. Education Program.

Iron overload promotes Cyclin D1 expression and alters cell cycle in mouse hepatocytes.

P. Brissot, O. Loréal, M. Troadec, 2006, Journal of hepatology.

Management of hemochromatosis. Hemochromatosis Management Working Group.

J. Cook, P. Brissot, K. Kowdley, 1998, Annals of internal medicine.

Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines.

G. Lescoat, D. Gilot, P. Brissot, 2000, Carcinogenesis.

Clinical Consequences of New Insights in the Pathophysiology of Disorders of Iron and Heme Metabolism.

G. Brittenham, P. Brissot, R. Moirand, 2000, Hematology. American Society of Hematology. Education Program.

Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases

P. Brissot, D. Guyader, A. Guillygomarc’h, 2006, Hepatology.

Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver

P. Brissot, R. Moirand, O. Loréal, 1995, Hepatology.

Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis

Marie-Pierre Dubé, Elizabeta Nemeth, Tomas Ganz, 2004, Nature Genetics.

Genetic hemochromatosis: Pathophysiology, diagnostic and therapeutic management.

P. Brissot, O. Loréal, P. Guggenbuhl, 2017, Presse medicale.

Molecular Testing in Hemochromatosis

P. Brissot, O. Loréal, A. Jouanolle, 2017 .

Mouse genetic background impacts both on iron and non-iron metals parameters and on their relationships

P. Brissot, O. Loréal, M. Island, 2015, BioMetals.

Sex and acquired cofactors determine phenotypes of ferroportin disease.

D. Vital-Durand, P. Brissot, O. Loréal, 2011, Gastroenterology.

Molecular diagnosis of genetic iron-overload disorders

P. Brissot, O. Loréal, A. Mosser, 2010, Expert review of molecular diagnostics.

Hepcidin induction limits mobilisation of splenic iron in a mouse model of secondary iron overload.

P. Brissot, O. Loréal, B. Turlin, 2010, Biochimica et biophysica acta.

Transcripts of ceruloplasmin but not hepcidin, both major iron metabolism genes, exhibit a decreasing pattern along the portocentral axis of mouse liver.

A. Guillouzo, B. Drénou, P. Brissot, 2008, Biochimica et biophysica acta.

Heterozygous Mutations in BMP6 Pro-peptide Lead to Inappropriate Hepcidin Synthesis and Moderate Iron Overload in Humans.

C. Beaumont, P. Brissot, D. Valla, 2016, Gastroenterology.

Heterozygous Mutations in BMP 6 Pro-peptide Lead to Inappropriate Hepcidin Synthesis and Moderate Iron Overload in Humans Running title : BMP 6 , gene for moderate hemochromatosis

C. Beaumont, P. Brissot, D. Valla, 2016 .

Management of Liver Complications in Haemoglobinopathies

P. Brissot, O. Loréal, 2014, Thalassemia Reports.

Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload.

P. Fergelot, J. L. Le Gall, P. Brissot, 2003, Journal of hepatology.

Clinical aspects of hemochromatosis.

P. Brissot, R. Moirand, D. Guyader, 2000, Transfusion science.

Inactivation of the hemochromatosis gene differentially regulates duodenal expression of iron-related mRNAs between mouse strains.

M. Bensaid, P. Brissot, O. Loréal, 2002, Gastroenterology.

Assessment of liver iron content in 271 patients: A reevaluation of direct and indirect methods

Michel Bourel, C. Beaumont, M. Simon, 1981 .

A novel N491S mutation in the human SLC11A2 gene impairs protein trafficking and in association with the G212V mutation leads to microcytic anemia and liver iron overload.

P. Brissot, O. Loréal, A. Mosser, 2011, Blood cells, molecules & diseases.

Chronic liver iron overload in the baboon by ferric nitrilotriacetate

A. Guillouzo, M. Simon, P. Brissot, 1987, Digestive Diseases and Sciences.

Magnetic resonance iron-free nodules in genetic hemochromatosis

P. Brissot, D. Guyader, Y. Gandon, 1999, American Journal of Gastroenterology.

gene discovery: revisiting the diagnostic strategy

P. Brissot, R. Moirand, D. Guyader, 1998 .

Hemochromatosis after the gene discovery: revisiting the diagnostic strategy.

P. Brissot, R. Moirand, D. Guyader, 1998, Journal of hepatology.

Ultrastructural sequences during liver iron overload in genetic hemochromatosis.

P. Brissot, Y. Deugnier, L. Powell, 1997, Journal of hepatology.

A reappraisal of hepatic siderosis in patients with end-stage cirrhosis: practical implications for the diagnosis of hemochromatosis.

P. Brissot, R. Moirand, O. Loréal, 1997, The American journal of surgical pathology.

Serum increase and liver overexpression of carbohydrate 19.9 antigen in patients with genetic haemochromatosis.

P. Brissot, R. Moirand, D. Guyader, 1994, Gut.

Differentiation Between Heterozygotes and Homozygotes in Genetic Hemochromatosis by Means of a Histological Hepatic Iron Index: A Study of 192 Cases

P. Brissot, R. Moirand, K. Summers, 1993, Hepatology.

Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations.

C. Jacquelinet, P. Brissot, R. Moirand, 1992, Gastroenterology.

Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients.

G. Lescoat, P. Brissot, R. Moirand, 1992, Journal of hepatology.

Iron load increases ferritin synthesis and secretion in adult human hepatocyte cultures.

G. Lescoat, P. Brissot, R. Moirand, 2008, Liver.

Acute infusions of bile salts increase biliary excretion of iron in iron-loaded rats.

A. Favier, P. Brissot, Y. Deugnier, 1991, Gastroenterology.

Increase in glycosylated and nonglycosylated serum ferritin in chronic alcoholism and their evolution during alcohol withdrawal.

G. Lescoat, P. Brissot, R. Moirand, 1991, Alcoholism, clinical and experimental research.

Hepatitis B virus infection markers in genetic haemochromatosis. A study of 272 patients.

C. Jacquelinet, P. Brissot, M. Bourel, 1991, Journal of hepatology.

Alcohol induction of ferritin expression in a human hepatoblastoma cell line (HEP G2).

G. Lescoat, P. Brissot, R. Moirand, 1990, Alcoholism, clinical and experimental research.

Iron induction of ferritin synthesis and secretion in human hepatoma cell (Hep G2) cultures.

G. Lescoat, P. Brissot, R. Moirand, 2008, Liver.

Comparative study between biochemical and histological methods and image analysis in liver iron overload.

P. Brissot, M. Bourel, Y. Deugnier, 1982, Journal of clinical pathology.

Ascorbic acid status in idiopathic hemochromatosis.

M. Simon, P. Brissot, M. Bourel, 1978, Digestion.

Pathophysiology and classification of iron overload diseases; update 2018.

P. Brissot, O. Loréal, M. Troadec, 2019, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

Management of Hemochromatosis

James Barton, J. Cook, P. Brissot, 1998, Annals of Internal Medicine.

Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment

P. Brissot, S. Ball, D. Rofail, 2011, Transfusion.

Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods.

C. Beaumont, M. Simon, P. Brissot, 1981, Gastroenterology.

Hypovitaminemia A in idiopathic hemochromatosis and hepatic cirrhosis. Role of retinol-binding protein and zinc.

M. Simon, P. Brissot, M. Bourel, 1978, Digestion.

Iron metabolism and related genetic diseases: A cleared land, keeping mysteries.

P. Brissot, O. Loréal, 2016, Journal of hepatology.

Haemochromatosis

C. McLaren, P. Brissot, B. Graaff, 2003 .

Duodenal mRNA expression of iron related genes in response to iron loading and iron deficiency in four strains of mice

M. Bensaid, P. Brissot, O. Loréal, 2002, Gut.

An HLA‐All Assoiciation with the hemochromatosis allele?

R. Fauchet, G. Edan, M. Simon, 1983 .

Carbonyl-iron supplementation induces hepatocyte nuclear changes in BALB/CJ male mice.

P. Brissot, O. Loréal, Y. Deugnier, 1999, Journal of hepatology.

The interaction of iron and the genome: For better and for worse.

P. Brissot, O. Loréal, M. Troadec, 2017, Mutation research.

Low penetrant hemochromatosis phenotype in eight families: no evidence of modifiers in the MHC region.

P. Fergelot, J. Mosser, J. L. Le Gall, 2001, Blood cells, molecules & diseases.

Polymorphisms in the HFE Gene

J. L. Le Gall, P. Brissot, R. Moirand, 1999, Human Heredity.

Ceruloplasmin deficiency does not induce macrophagic iron overload: lessons from a new rat model of hereditary aceruloplasminemia

P. Brissot, S. Remy, L. Tesson, 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment.

P. Brissot, Y. Deugnier, B. Turlin, 1997, Gut.

Genetics of Hemochromatosis: HLA Association and Mode of Inheritance a

R. Fauchet, M. Simon, P. Brissot, 1988 .

Is the HLA‐linked haemochromatosis allele implicated in idiopathic refractory sideroblastic anaemia?

M. Krempf, R. Fauchet, B. Grosbois, 1985, British journal of haematology.

Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C.

P. Brissot, D. Guyader, Anne-Sophie Thirouard, 2007, Journal of hepatology.

Idiopathic hemochromatosis: a study of biochemical expression in 247 heterozygous members of 63 families: evidence for a single major HLA-linked gene.

R. Fauchet, C. Beaumont, M. Simon, 1980, Gastroenterology.

Characterization of non-transferrin-bound iron clearance by rat liver.

P. Brissot, R. Weisiger, W. Ma, 1986, The Journal of biological chemistry.

Iron excess treatable by copper supplementation in acquired aceruloplasminemia: a new form of secondary human iron overload?

P. Brissot, S. Belliard, O. Loréal, 2009, Blood.

MRI quantification of splenic iron concentration in mouse

P. Brissot, H. Saint-Jalmes, Y. Gandon, 2010, Journal of magnetic resonance imaging : JMRI.

[The diagnosis of hemochromatosis in the era of the gene].

P. Brissot, R. Moirand, D. Guyader, 1999, Annales d'endocrinologie.

EASL International Consensus Conference on Haemochromatosis Co-sponsored by the World Health Organization *

P. Brissot, L. Powell, 2022 .

Low hepatic iron concentration: evaluation of two complementary methods, colorimetric assay and iron histological scoring.

P. Brissot, J. Delattre, Y. Deugnier, 1999, Journal of clinical pathology.

Idiopathic hemochromatosis and iron overload in alcoholic liver disease: differentiation by HLA phenotype.

R. Fauchet, G. Edan, M. Simon, 1977, Gastroenterology.

Diagnosis and current treatments for primary iron overload

P. Brissot, 2007, American journal of hematology.

Hemochromatosis: a model of metal-related human toxicosis

P. Brissot, O. Loréal, F. Gaboriau, 2016, Environmental Science and Pollution Research.

The relationship between fatty acid peroxidation and α-tocopherol consumption in isolated normal and transformed hepatocytes

G. Lescoat, P. Brissot, J. Cillard, 1993, Lipids.

Cytoprotection and iron mobilization in rat hepatocyte cultures by a new synthetic dihydroxamate chelator.

G. Lescoat, P. Brissot, I. Morel, 1999, Toxicology letters.

Inhibition of iron toxicity in human hepatocyte cultures by pyoverdins Pa A and Pf, the peptidic siderophores of Pseudomonas aeruginosa and fluorescens.

G. Lescoat, P. Brissot, O. Loréal, 2008, Liver.

Iron may induce both DNA synthesis and repair in rat hepatocytes stimulated by EGF/pyruvate.

G. Lescoat, B. Drénou, P. Brissot, 1997, Journal of hepatology.

Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94.

G. Lescoat, P. Brissot, O. Loréal, 1995, Journal of hepatology.

EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron-loaded hepatocyte culture: comparison with that of desferrioxamine.

G. Lescoat, P. Brissot, J. Cillard, 1995, Free radical biology & medicine.

Inhibition of iron toxicity in rat hepatocyte cultures by pyoverdin Pa A, the peptidic fluorescent siderophore of Pseudomonas aeruginosa.

G. Lescoat, P. Brissot, R. Moirand, 1993, Toxicology in vitro : an international journal published in association with BIBRA.

Inhibition of iron overload toxicity in rat hepatocyte cultures by pyoverdin Pf, the siderophore of Pseudomonas fluorescens.

G. Lescoat, P. Brissot, A. Ocaktan, 1992, Biochemical pharmacology.

Chronic iron overload inhibits protein secretion by adult rat hepatocytes maintained in long-term primary culture.

G. Lescoat, M. Rissel, P. Brissot, 1989, European journal of cell biology.

Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states.

P. Brissot, R. Weisiger, Teresa, 1985, The Journal of clinical investigation.

Rare HFE variants are the most frequent cause of hemochromatosis in non‐c282y homozygous patients with hemochromatosis

X. Causse, P. Brissot, H. Hamdi-Rozé, 2016, American journal of hematology.

Serum α‐L‐Fucosidase: A New Marker for the Diagnosis of Primary Hepatic Carcinoma?

P. Brissot, M. Bourel, Y. Deugnier, 1984 .

Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype

D. Girelli, D. Swinkels, N. Milman, 2018, Hepatology International.

An HLA-All association with the hemochromatosis allele?

R. Fauchet, G. Edan, M. Simon, 1983, Clinical genetics.

[Hyperferritinemia not related to hemochromatosis].

P. Brissot, C. Le Lan, Y. Deugnier, 2009, Gastroenterologie clinique et biologique.

Stearoyl coenzyme A desaturase 1 expression and activity are increased in the liver during iron overload.

P. Legrand, P. Brissot, O. Loréal, 2001, Biochimica et biophysica acta.

Effect of ursodeoxycholic acid on liver iron stores and distribution in rats with normal or iron-supplemented diet.

G. Lescoat, P. Brissot, O. Loréal, 2008, Liver.

Hepcidin in iron metabolism.

P. Brissot, O. Loréal, M. Troadec, 2005, Current protein & peptide science.

Clinical management of hemochromatosis: current perspectives

P. Brissot, O. Loréal, P. Guggenbuhl, 2017 .

[Hereditary hemochromatosis: presenting manifestations and diagnostic delay].

P. Brissot, B. Gasser, F. Courtois, 2014, La Revue de medecine interne.

Elevated parathyroid hormone 44-68 and osteoarticular changes in patients with genetic hemochromatosis.

P. Brissot, R. Moirand, Y. Deugnier, 1999, Arthritis and rheumatism.

Variable age of onset and clinical severity in transferrin receptor 2 related haemochromatosis: novel observations

X. Causse, P. Brissot, S. Cunat, 2013, British journal of haematology.

Reinforced interferon alpha‐2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial

P. Marcellin, D. Dhumeaux, D. Samuel, 2003, Journal of viral hepatitis.

Effects of phlebotomy therapy on cytochrome P450 2e1 activity and oxidative stress markers in dysmetabolic iron overload syndrome: a randomized trial

P. Brissot, A. Guillygomarc’h, F. Laine, 2006, Alimentary pharmacology & therapeutics.

[Sinusoid dilatation and the use of oral contraceptives. Apropos of a case with a review of the literature].

D. Heresbach, P. Brissot, M. Bourel, 1988, Annales de gastroenterologie et d'hepatologie.

Laboratory medicine and iron overload: diagnostic and therapeutic aspects

P. Brissot, O. Loréal, M. Ropert, 2020 .

Transferrin Electronic Detector for Iron Disease Diagnostics

M. Harnois, P. Brissot, O. Loréal, 2006, 2006 5th IEEE Conference on Sensors.

Deferoxamine arrests in vitro the proliferation of porcine hepatocyte in G1 phase of the cell cycle.

G. Lescoat, B. Drénou, P. Brissot, 2008, Liver.

A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon.

P. Brissot, D. Guyader, Y. Deugnier, 1999 .

Novel mutations in the bone morphogenetic protein 6 gene in patients with iron overload and non-homozygous genotype for the HFE p.Cys282Tyr mutation.

P. Brissot, T. G. Oliveira, P. C. Santos, 2020, Blood cells, molecules & diseases.

Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing.

P. Brissot, K. Boudjema, R. Moirand, 2002, Journal of hepatology.

Haemochromatosis revisited

P. Brissot, P. C. Santos, Aline Morgan Alvarenga, 2022, World journal of hepatology.

Hereditary hemochromatosis

P. Brissot, 2013, Hematology.

Iron overload of the liver in the baboon. An ultrastructural study.

A. Guillouzo, P. Brissot, M. Bourel, 1985, Journal of hepatology.

Hepatocyte iron loading capacity is associated with differentiation and repression of motility in the HepaRG cell line.

Nolwenn Le Meur, Nathalie Théret, Olivier Loréal, 2006, Genomics.

Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism

G. Lescoat, P. Brissot, F. Gaboriau, 2007, Cell proliferation.

Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures.

G. Lescoat, P. Brissot, J. Cillard, 1993, Biochemical pharmacology.

[Hepatic manifestations of Horton's disease].

P. Brissot, M. Bourel, D. Guérin, 1978, Annales de medecine interne.

Aminotransferase Levels and Silymarin in de novo Tacrine-Treated Patients with Alzheimer’s Disease

P. Brissot, J. Gandon, H. Allain, 1999, Dementia and Geriatric Cognitive Disorders.

Miscellaneous non-inflammatory musculoskeletal conditions. Haemochromatosis: the bone and the joint.

P. Brissot, O. Loréal, P. Guggenbuhl, 2011, Best practice & research. Clinical rheumatology.

Miscellaneous non-inflammatory musculoskeletal conditions. Haemochromatosis: the bone and the joint.

P. Brissot, O. Loréal, P. Guggenbuhl, 2011, Best practice & research. Clinical rheumatology.

The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.

G. Lescoat, P. Brissot, F. Gaboriau, 2006, European journal of pharmacology.

A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis

P. Malfertheiner, H. Bonkovsky, P. Brissot, 2010, Hepatology.

A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.

H. Bonkovsky, P. Brissot, W. Stremmel, 2009 .

Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG

G. Lescoat, P. Brissot, O. Loréal, 2010, BioMetals.

[Respective value of serum activity of alkaline phosphatase, gamma-glutamyl transpeptidase and 5'-nucleotidase in the diagnosis of intra- and extrahepatic cholestasis].

P. Brissot, D. Guyader, Y. Deugnier, 1997, Gastroentérologie Clinique et Biologique.

High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver.

A. Guillouzo, P. Brissot, M. Bourel, 1982, Cell biology international reports.

Lysosomal enzyme activities during ageing of adult human liver cell lines

A. Guillouzo, P. Brissot, D. Glaise, 1979, Mechanisms of Ageing and Development.

Long term follow up of chronic hepatitis by serial liver biopsies in HBs positive haemodialysis patients. Role of hepatotoxic drugs.

P. Brissot, A. Meyrier, P. Simon, 1978, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

Mössbauer spectroscopy study of iron overloaded livers.

P. Brissot, R. Girot, F. Dumas, 1985, Biochimie.

Non-transferrin bound iron: a key role in iron overload and iron toxicity.

P. Brissot, O. Loréal, C. Le Lan, 2012, Biochimica et biophysica acta.

Iron, hepcidin, and the metal connection

P. Brissot, O. Loréal, P. Guggenbuhl, 2014, Front. Pharmacol..

Fiber evanescent wave spectroscopy using the mid-infrared provides useful fingerprints for metabolic profiling in humans.

Olivier Sire, Bruno Bureau, Jacques Lucas, 2009, Journal of biomedical optics.

Short-term prednisolone followed by recombinant human alpha-interferon alone or combined with adenine-arabinoside in chronic hepatitis B. A prospective and randomized trial.

C. Jacquelinet, G. Lescoat, P. Brissot, 1991, Journal of hepatology.

A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload

C. Beaumont, P. Brissot, B. Grandchamp, 2009, Haematologica.

Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging.

Y Gandon, M Carsin, P. Brissot, 1994, Radiology.

Genetic hemochromatosis update.

G. Lescoat, P. Brissot, O. Loréal, 2005, Acta gastro-enterologica Belgica.

Interferon and ursodeoxycholic acid combined therapy in the treatmet of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients

C. Jacquelinet, P. Brissot, R. Moirand, 1995, Hepatology.

[Transmission of viruses (from A to E) and prevention].

P. Brissot, H. Jouanolle, 1990, La Revue du praticien.

Use of adult human hepatocytes in primary culture for the study of clometacin-induced immunoallergic hepatitis.

A. Guillouzo, P. Brissot, C. Guguen-Guillouzo, 1991, Toxicology in vitro : an international journal published in association with BIBRA.

In vitro demonstration of synergy between radionuclide and chemotherapy.

G. Lescoat, P. Brissot, J. Raoul, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Antiproliferative effect of deferiprone on the Hep G2 cell line.

G. Lescoat, B. Drénou, P. Brissot, 1998, Biochemical pharmacology.

Iron mobilisation and cellular protection by a new synthetic chelator O-Trensox.

G. Lescoat, P. Brissot, R. Crichton, 1998, Biochemical pharmacology.

Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function.

T. Ganz, P. Brissot, K. Boudjema, 2005, Blood.

Strain and gender modulate hepatic hepcidin 1 and 2 mRNA expression in mice.

P. Brissot, O. Loréal, M. Roth, 2004, Blood cells, molecules & diseases.

Comparative analysis of mouse hepcidin 1 and 2 genes: evidence for different patterns of expression and co‐inducibility during iron overload 1

P. Brissot, M. Alizadeh, O. Loréal, 2003, FEBS letters.

Haemochromatosis

C. McLaren, P. Brissot, B. Graaff, 2018, Nature Reviews Disease Primers.

Chronic hepatic cytolysis revealing a pheochromocytoma.

P. Brissot, A. Manunta, T. Wallenhorst, 2012, Clinics And Research in Hepatology and Gastroenterology.

Non-HFE hemochromatosis: pathophysiological and diagnostic aspects.

P. Brissot, O. Loréal, E. Bardou-Jacquet, 2014, Clinics and research in hepatology and gastroenterology.

A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis

Olivier Loréal, P. Brissot, O. Loréal, 2009, Haematologica.

Current approach to hemochromatosis.

P. Brissot, O. Loréal, C. Le Lan, 2008, Blood reviews.

Iron and the liver: update 2008.

P. Brissot, O. Loréal, Y. Deugnier, 2008, Journal of hepatology.

Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance.

J. Mosser, P. Brissot, A. Mosser, 2007, American journal of human genetics.

C/EBPα Regulates Hepatic Transcription of Hepcidin, an Antimicrobial Peptide and Regulator of Iron Metabolism

D. Gilot, P. Brissot, K. Boudjema, 2002, The Journal of Biological Chemistry.

Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: a biological and physicochemical study

G. Lescoat, P. Brissot, P. Loyer, 2004 .

Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.

P. Brissot, M. Cappellini, Y. Deugnier, 2011, Gastroenterology.

Modulation of cell proliferation and polyamine metabolism in rat liver cell cultures by the iron chelator O-trensox

G. Lescoat, P. Brissot, F. Gaboriau, 2006, Biometals.

Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats.

G. Lescoat, P. Brissot, G. Zanninelli, 1997, Journal of hepatology.

A point mutation in the bulge of the iron-responsive element of the L ferritin gene in two families with the hereditary hyperferritinemia-cataract syndrome.

C. Beaumont, P. Brissot, M. Martín, 1998, Blood.

G. Lescoat, P. Brissot, P. Loyer, 2001, Biochemical pharmacology.

EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH)

D. Swinkels, S. Patton, P. Brissot, 2015, European Journal of Human Genetics.

[The cardiomyopathy of idiopathic hemochromatosis].

J. Daubert, M. Simon, J. Hespel, 1978, Archives des maladies du coeur et des vaisseaux.

Iron as a Therapeutic Target in HFE-Related Hemochromatosis: Usual and Novel Aspects

P. Brissot, O. Loréal, P. Guggenbuhl, 2018, Pharmaceuticals.

Rare anemias due to genetic iron metabolism defects.

P. Brissot, O. Loréal, M. Troadec, 2018, Mutation research.

The labile iron pool of hepatocytes in chronic and acute iron overload and chelator-induced iron deprivation.

P. Brissot, G. Zanninelli, O. Loréal, 2002, Journal of hepatology.

EASL International Consensus Conference on Haemochromatosis.

P. Brissot, L. Powell, P. Adams, 2000, Journal of hepatology.

GATA-4 transcription factor regulates hepatic hepcidin expression.

P. Brissot, O. Loréal, M. Island, 2011, The Biochemical journal.

Uremia and the liver. I. The liver and erythropoiesis in chronic renal failure.

P. Brissot, A. Meyrier, P. Simon, 1981, Nephron.

Hemochromatosis at the intersection of classical medicine and molecular biology.

P. Brissot, P Brissot, 2001, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

Evaluation of a liver transplant by Tc-99m dimethyl-IDA scintigraphy.

P. Brissot, M. Bourel, J. Le Jeune, 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis

P. Brissot, K. Boudjema, D. Guyader, 2014, Hepatology.

The origin and spread of the HFE-C282Y haemochromatosis mutation

M. Worwood, P. Brissot, K. Robson, 2004, Human Genetics.

Carcinoma of the Hepatic Hilus Surgical Management and the Case for Resection

P. Brissot, J. Campion, B. Launois, 1979, Annals of surgery.

Monoclonal anti‐transferrin antibody: A paradigm for better understanding of iron metabolism

P. Brissot, O. Loréal, P. Leroyer, 2015, American journal of hematology.

What’s Important and New in Hemochromatosis?

P. Brissot, E. Brissot, 2020, Clinical hematology international.

[Haemochromatoses. New understanding, new treatments].

P. Brissot, 2009, Gastroenterologie clinique et biologique.

Modulation of albumin secretion by ornithine alpha-ketoglutarate in adult rat hepatocyte cultures and a human hepatoma cell line (HepG2).

G. Lescoat, P. Brissot, M. Bourel, 1989, Annals of nutrition & metabolism.

Second Round Robin for plasma hepcidin methods : First steps toward harmonization

M. Muckenthaler, M. Fleming, D. Ward, 2012 .

High vascular endothelial growth factor (VEGF) expression in chemically-induced hepatic microcancers in mice.

P. Brissot, O. Loréal, Y. Deugnier, 2002, Journal of hepatology.

Serum Transferrin Saturation Increase Is Associated With Decrease of Antibacterial Activity of Serum in Patients With HFE-Related Genetic Hemochromatosis

P. Brissot, O. Loréal, A. Jolivet-Gougeon, 2008, The American Journal of Gastroenterology.

A new syndrome of liver iron overload with normal transferrin saturation

Olivier Loréal, P. Brissot, R. Moirand, 1997, The Lancet.

187 A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION TRIAL USING THE ONCE-DAILY ORAL CHELATOR DEFERASIROX TO TREAT IRON OVERLOAD IN HFE-RELATED HEREDITARY HEMOCHROMATOSIS: FINAL RESULTS

P. Malfertheiner, H. Bonkovsky, P. Brissot, 2009 .

Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH).

H. Bonkovsky, P. Brissot, C. Niederau, 2007 .

DIAGNOSTIC AND TREATMENT OF INHERITED HAEMOCHROMATOSIS

P. Brissot, O. Loréal, M. Island, 2009 .

Involvement of polyamines in iron(III) transport in human intestinal Caco-2 cell lines

G. Lescoat, P. Brissot, O. Loréal, 2013, Molecular and Cellular Biochemistry.

Idiopathic hemochromatosis: A study of biochemical expression in 247 heterozygous members of 63 families: Evidence for a single major HLA-linked gene

R. Fauchet, C. Beaumont, M. Simon, 1980 .

Portable hemoglobinometer is a reliable technology for the follow-up of venesections tolerance in hemochromatosis.

P. Brissot, M. Latournerie, M. Ropert, 2015, Clinics and research in hepatology and gastroenterology.

[Alpha-L-fucosidase. A new marker of primary liver cancer?].

P. Brissot, M. Bourel, Y. Deugnier, 1983, Presse medicale.

The pioneering role of the Rennes School in haemochromatosis

P. Brissot, coLLoques de L’InstItut, 2017 .

Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen)

P. Brissot, K. Boudjema, J. Raoul, 2002, Cancer Chemotherapy and Pharmacology.

Diagnosit value of erythrocyte-free polyamines and histaminemia in malignant hepatic tumors and in liver cirrhosis

P. Brissot, M. Bourel, J. Moulinoux, 1985 .

Hemochromatosis classification: update and recommendations by the BIOIRON Society.

D. Girelli, M. Muckenthaler, P. Brissot, 2021, Blood.

Uremia and the liver. II. Drugs and the liver in the uremic patient.

P. Brissot, A. Meyrier, P. Simon, 1981, Nephron.

Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) or Deferoxamine Results in Reduced Hepatocellular Inflammation and Improved Liver Function in Patients with Transfusion-Dependent Anemia.

J. Ford, P. Brissot, A. Thompson, 2005 .

Diagnostic value of erythrocyte-free polyamines and histaminemia in malignant hepatic tumors and in liver cirrhosis.

P. Brissot, M. Bourel, J. Moulinoux, 1985, Clinica chimica acta; international journal of clinical chemistry.

Simultaneous measurements of conjugated dienes and free malondialdehyde, used as a micromethod for the evaluation of lipid peroxidation in rat hepatocyte cultures.

G. Lescoat, P. Brissot, J. Cillard, 1993, Chemistry and physics of lipids.

[Hyper-ferritinemia and Gaucher disease].

P. Brissot, R. Moirand, D. Guyader, 1996, Gastroenterologie clinique et biologique.

[A new case of hepatitis due to glafenine].

P. Brissot, M. Bourel, F. Cartier, 1982, Gastroentérologie Clinique et Biologique.

alpha-Fetoprotein screening in patients with idiopathic hemochromatosis and liver cirrhosis.

P. Brissot, M. Bourel, J. Chayvialle, 1977, Digestion.

Chromosomal aberrations in patients with primary biliary cirrhosis

M. Manns, P. Brissot, U. Nestle, 1990, Human Genetics.

[Iron overload and HFE gene].

P. Brissot, R. Moirand, D. Guyader, 1999, Gastroenterologie clinique et biologique.

Non‐invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis

P. Brissot, R. Moirand, D. Guyader, 2015, Liver international : official journal of the International Association for the Study of the Liver.

The clinical relevance of new insights in iron transport and metabolism.

P. Brissot, O. Loréal, M. Troadec, 2004, Current hematology reports.

Spleen iron, molybdenum, and manganese concentrations are coregulated in hepcidin‐deficient and secondary iron overload models in mice

P. Brissot, O. Loréal, P. Guggenbuhl, 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Diagnostic evaluation of hereditary hemochromatosis (HFE and non-HFE).

P. Brissot, E. Bardou-Jacquet, 2014, Hematology/oncology clinics of North America.

Biliary excretion of plasma non-transferrin-bound iron in rats: pathogenetic importance in iron-overload disorders.

J. Zeind, P. Brissot, G. Zanninelli, 1994, The American journal of physiology.

Letters to the Editor: Non-alcoholic steatohepatitis with iron: part of insulin resistanceassociated hepatic iron overload?

P. Brissot, R. Moirand, A. Guillygomarc’h, 2000 .

Non-alcoholic steatohepatitis with iron: part of insulin resistance-associated hepatic iron overload?

P. Brissot, R. Moirand, A. Guillygomarc’h, 2000, Journal of hepatology.

Reduction of liver iron content following tratment of chronic hepatitis C

P. Brissot, R. Moirand, Y. Deugnier, 1995 .

A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon

P. Brissot, D. Guyader, Y. Deugnier, 1999, American Journal of Gastroenterology.

Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases.

P. Brissot, D. Guyader, Y. Deugnier, 1993, Gastroenterology.

[Histochemical detection of hepatic iron. A comparative study of four stains].

P. Brissot, R. Moirand, O. Loréal, 1992, Annales de pathologie.

Ferroportin Diseases: Functional Studies, a Link Between Genetic and Clinical Phenotype

P. Brissot, O. Loréal, A. Mosser, 2013, Human mutation.

Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption

P. Brissot, R. Moirand, D. Guyader, 2004, Hepatology.

Serum alpha-L-fucosidase: a new marker for the diagnosis of primary hepatic carcinoma?

P. Brissot, M. Bourel, Y. Deugnier, 1984, Hepatology.

[Porphyrins and idiopathic hemochromatosis. Study of 32 cases (author's transl)].

M. Simon, P. Brissot, M. Bourel, 1978, Gastroenterologie clinique et biologique.

The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis

P. Brissot, R. Moirand, Y. Deugnier, 1997, Hepatology.

Differentiation Between Heterozygotes and Homozygotes in Genetic Hemochromatosis by Means of a Histological Hepatic Iron Index: A Study of 192 Cases

P. Brissot, R. Moirand, K. Summers, 1993, Hepatology.

Regulation of ferritin expression by alcohol in a human hepatoblastoma cell line and in rat hepatocyte cultures.

G. Lescoat, P. Brissot, R. Moirand, 1995, Journal of Hepatology.

Transient transcriptional inhibition of the transferrin gene by cyclic AMP

A. Munnich, P. Brissot, S. Vaulont, 1985, FEBS letters.

HFE based re-evaluation of heterozygous hemochromatosis.

J. L. Le Gall, P. Brissot, R. Moirand, 2002, American journal of medical genetics.